These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6202669)

  • 1. Biological evaluation of stability of 5-azacytidine.
    Li LH; Buskirk HH; Blowers CL; Neil GL; Hanka LJ
    J Antibiot (Tokyo); 1984 Apr; 37(4):419-21. PubMed ID: 6202669
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
    Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
    Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice.
    Presant CA; Coulter D; Valeriote F; Vietti TJ
    J Natl Cancer Inst; 1981 Jun; 66(6):1151-4. PubMed ID: 6165854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26.
    Chiuten DF; Muggia FM; Johnson RK
    Cancer Treat Rep; 1979; 63(11-12):1857-62. PubMed ID: 93512
    [No Abstract]   [Full Text] [Related]  

  • 5. Dihydro-5-azacytidine hydrochloride, a biologically active and chemically stable analog of 5-azacytidine.
    Beisler JA; Abbasi MM; Driscoll JS
    Cancer Treat Rep; 1976 Nov; 60(11):1671-4. PubMed ID: 66095
    [No Abstract]   [Full Text] [Related]  

  • 6. [Possibilities for the clinical use of 5-azacytidine].
    Veselý J; Cihák A
    Vopr Onkol; 1977; 23(10):65-73. PubMed ID: 74127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of the reduction in viability of cultured L1210 leukemia cells exposed to 5-azacytidine (NSC-102816).
    Lloyd HH; Dulmadge EA; Wilkoff LJ
    Cancer Chemother Rep; 1972 Oct; 56(5):585-91. PubMed ID: 4119906
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
    Beisler JA; Abbasi MM; Kelley JA; Driscoll JS
    J Med Chem; 1977 Jun; 20(6):806-12. PubMed ID: 69026
    [No Abstract]   [Full Text] [Related]  

  • 9. Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.
    Beisler JA
    J Med Chem; 1978 Feb; 21(2):204-8. PubMed ID: 74412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
    Presant CA; Vietti T; Valeriote F
    Cancer Res; 1975 Aug; 35(8):1926-30. PubMed ID: 50128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the alpha-D-anomer of 5-aza-2'-deoxycytidine on L1210 mouse leukemic cells in vitro and in vivo.
    Veselý J; Pískala A
    Cancer Res; 1984 Nov; 44(11):5165-8. PubMed ID: 6207913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
    Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
    Neil GL; Berger AE; Bhuyan BK; DeSante DC
    Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in mice.
    Zaharko DS; Covey JM
    Invest New Drugs; 1985; 3(4):323-9. PubMed ID: 2417983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of intercalator-induced deoxyribonucleic acid scission and cytotoxicity in murine leukemia cells treated with 5-azacytidine.
    Zwelling LA; Minford J; Nichols M; Glazier RI; Shackney S
    Biochem Pharmacol; 1984 Dec; 33(23):3903-6. PubMed ID: 6210091
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine.
    Heby O; Russell DH
    Cancer Res; 1973 Jan; 33(1):159-65. PubMed ID: 4118428
    [No Abstract]   [Full Text] [Related]  

  • 18. Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.
    Momparler RL; Momparler LF; Samson J
    Int J Cancer; 1982 Sep; 30(3):361-64. PubMed ID: 6182115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity.
    Hashida M; Takakura Y; Matsumoto S; Sasaki H; Kato A; Kojima T; Muranishi S; Sezaki H
    Chem Pharm Bull (Tokyo); 1983 Jun; 31(6):2055-63. PubMed ID: 6196134
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
    Presant CA; Vietti TJ; Valeriote F; Coulter DM
    J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.